With an increasing prevalence during the past decades, atopic dermatitis has become a
global health issue. A literature search following a targeted approach was undertaken to …

Objectives There is increasing recognition that insufficient attention has been paid to the
choice of outcomes measured in clinical trials. The lack of a standardized outcome …

Background Nemolizumab is a subcutaneously administered humanized monoclonal
antibody against interleukin-31 receptor A, which is involved in pruritus and inflammation in …

Core outcome sets are critically important outcomes that should be measured in clinical
trials. Their absence in atopic dermatitis is a form of research waste and impedes combining …

Atopic dermatitis (AD) is a chronic, pruritic, inflammatory dermatosis that affects up to 25% of
children and 2% to 3% of adults. This guideline addresses important clinical questions that …

Background Scoring systems for assessing the signs of atopic dermatitis (AD) are complex
and difficult to interpret. Severity strata are helpful to interpret these assessments properly …

Atopic dermatitis (AD) is one of the most common inflammatory skin diseases. AD is driven
by barrier dysfunction and abnormal immune activation of T helper (Th) 2, Th22, and varying …

Emollients and moisturisers for eczema - van Zuuren, EJ - 2017 | Cochrane Library Skip to
Content Cookies Our site uses cookies to improve your experience. You can find out more …

Книга посвящена систематизации количественной оценки дерматологических
заболеваний. Во второе издание вошли зарекомендовавшие себя на практике и …

The lack of core outcome sets for atopic eczema (AE) is a major obstacle for advancing
evidence-based treatment. The global Harmonising Outcome Measures for Eczema (HOME) …